Clin2
NCT07276100Possibly a fitRecruiting

Fecal transplant to help liver cancer that worsened on first treatment

Hepato Cellular Carcinoma (HCC)

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
15 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have been on atezolizumab and bevacizumab for at least 4 months and your cancer still got worse.
  • You have at least one liver tumor that has not been treated yet and can be measured on a scan.
  • You are up and around most of the day (ECOG 0 or 1).
  • Your liver function is good (Child-Pugh A, meaning no or mild liver damage).
  • Your blood counts and kidney/liver lab values are within safe limits.
  • You do not have active or serious autoimmune disease, brain metastases, uncontrolled bleeding, or recent major surgery or infection.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07690683Not yet recruiting
Gut health and immunotherapy for advanced liver cancer

This trial studies how the gut (your digestive system) affects how well immunotherapy works for advanced liver cancer. You'll have a colonoscopy (a test to look inside your bowel) and provide samples, which could help doctors improve treatment for you and others.

Roma
NCT05690048Recruiting· Phase 2
Fecal transplant to help liver cancer respond to standard drugs

This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.

Heidelberg, Baden-Wurttemberg
NCT06643533Not yet recruiting
Fecal transplant to fight drug resistance in liver cancer

This trial tests whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help your liver cancer become sensitive again to treatment that has stopped working. It may help reverse drug resistance and improve outcomes for people with advanced liver cancer.

NCT06563947Recruiting· Phase 2
Fecal transplant for advanced liver cancer after treatment stops working

This trial tests whether giving a fecal transplant (a procedure that replaces the bacteria in your gut) can help people with advanced liver cancer whose current treatment has stopped working. It may help boost your immune system to fight the cancer.

Shenzhen
NCT07847671Not yet recruiting· Phase 2
Fecal transplant with immunotherapy and bevacizumab for advanced liver cancer

This trial tests combining a fecal transplant (healthy donor bacteria) with two drugs—QL1706 (an immunotherapy) and bevacizumab (a blood vessel blocker)—for people with advanced liver cancer that hasn't been treated before. The goal is to see if this combination can shrink tumors or slow their growth.

Tianjin
NCT06551272Recruiting· Phase 2
Gut bacteria change to help immunotherapy for liver cancer

This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.

Bobigny

Hear when a new Hepato Cellular Carcinoma (HCC) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.